Noncanonical mRNA decay by the endoplasmic-reticulum stress sensor IRE1 α promotes cancer-cell survival

Adrien Le Thomas¹, Elena Ferri^{2,3}, Scot Marsters¹, Jonathan M. Harnoss¹, Zora Modrusan⁴, Weihan Li^{5,6}, Joachim Rudolph³, Weiru Wang², Thomas D. Wu^{7,8}, Peter Walter^{5,6,8}, and Avi Ashkenazi^{1,8}

Departments of ¹Cancer Immunology, ²Structural Biology, ³Discovery Chemistry
⁴Microchemistry Proteomics and Lipidomics, ⁷Bioinformatics, Genentech, Inc., South
San Francisco, CA 94080 USA; ⁵Howard Hughes Medical Institute; ⁶University of
California, San Francisco, CA 94158 USA; ⁸Corresponding authors

ABSTRACT

Eukaryotic IRE1 mitigates endoplasmic-reticulum (ER) stress by orchestrating the unfolded-protein response (UPR). IRE1 spans the ER membrane, and signals through a cytosolic kinase-endoribonuclease module. The endoribonuclease generates the transcription factor XBP1s by intron excision between similar RNA stem-loop endomotifs, and depletes select cellular mRNAs through regulated IRE1-dependent decay (RIDD). Paradoxically, mammalian RIDD seemingly targets only mRNAs with XBP1-like endomotifs, while in flies RIDD exhibits little sequence restriction. By comparing nascent and total IRE1 α -controlled mRNAs in human breast cancer cells, we discovered not only canonical endomotif-containing RIDD substrates, but also many targets lacking recognizable motifs—degraded by a process we coin RIDDLE, for RIDD lacking endomotif. IRE1 α displayed two basic endoribonuclease modalities: endomotif-specific cleavage, minimally requiring dimers; and endomotif-independent promiscuous processing, requiring phospho-oligomers. An oligomer-deficient mutant that did not support RIDDLE failed to rescue cancer-cell viability. These results link IRE1 α oligomers, RIDDLE, and cell survival, advancing mechanistic understanding of the UPR.

INTRODUCTION:

The ER mediates folding of newly synthesized secretory and membrane proteins. Excess folding demand leads to ER accumulation of misfolded proteins, causing ER stress. This engages an intracellular signaling network, dubbed the unfolded protein response (UPR), to reestablish homeostasis¹⁻³. The mammalian UPR entails three ER-transmembrane proteins: IRE1 α , PERK, and ATF6, which coordinate adaptive changes to expand ER capacity while abating ER load^{1,3,4}. If adaptation fails, the UPR triggers apoptotic cell death⁴⁻⁶. UPR dysregulation contributes to several diseases⁷⁻¹¹. Cancer cells often leverage the UPR, including IRE1 α , to circumvent ER stress and maintain malignant growth^{10,12-17}. Better mechanistic understanding would help elucidate the UPR's role in disease, and advance its potential for medical translation.

IRE1 α comprises ER-luminal and transmembrane domains, and a cytosolic kinase-endoribonuclease (KR) module^{18,19}. Unfolded-protein sensing by the luminal domain drives IRE1 α homodimerization, kinase-mediated *trans*-autophosphorylation, and endoribonuclease activation¹⁹⁻²⁴. The RNase produces the transcription factor spliced X-box binding protein 1 (XBP1s), and depletes multiple cellular mRNAs through regulated IRE1-dependent decay (RIDD)²⁵⁻²⁷. XBP1s-target genes support protein folding and ER-associated degradation (ERAD)²⁸. IRE1 α cleaves unspliced XBP1 α mRNA at two stem-loop endomotifs, removing a 26-nt intron²⁹⁻³¹, and RtcB ligates the severed exons, generating XBP1s³²⁻³⁴. XBP1u cleavage at each splice site requires an energetically stable stem, as well as a 7-nt consensus sequence CNG|CAGC within the loop, with scission between G and C in the third and fourth positions^{34,35}.

RIDD remains puzzling^{27,36}. In the budding yeast *S. cerevisiae*, IRE1 triggers non-conventional mRNA splicing of the *XPB1* ortholog *HAC1*, yet lacks RIDD activity²⁶. Conversely, in the fission yeast *S. pombe*, IRE1 performs RIDD, which targets a UG|CU core motif within variably sized stem-loop structures, but *HAC1* mRNA is absent³⁷. In the fruit fly *D. melanogaster*, RIDD primarily targets ER-bound mRNAs, with minimal sequence and unknown structure restriction^{26,38,39}. By contrast, in mammals, known RIDD substrates seem to possess and require for cleavage an XPB1-like consensus loop sequence CNGCAGN, enclosed by a stable stem⁴⁰⁻⁴³. Besides ER load, mammalian RIDD regulates additional cellular functions, including triglyceride and cholesterol metabolism⁴⁴; apoptosis signaling through DR5⁴⁵⁻⁴⁷; protective autophagy via BLOC1S1 (BLOS1)⁴⁸; and DNA repair through Ruvbl1^{49,50}. A canonical stem-loop endomotif is necessary but not sufficient to predict mammalian RIDD, while translational stalling can enhance mRNA depletion⁴¹. Although other mechanisms, such as NO-GO decay and the cytosolic exosome, have been implicated in completing degradation after endomotif-directed mRNA cleavage by IRE1⁵¹, it is unknown whether IRE1 itself can conduct full RNA digestion. Autophosphorylation supporting IRE1 oligomerization^{22,45,50,52} and the resulting higher-order assemblies may affect RNase output^{21,22,53-57}. However, the specific requirements for endomotif-restricted vs. non-restricted IRE1 RNase activity remain ill-defined, and the significance of the latter in cells of higher metazoans remains elusive.

To investigate the scope of RIDD in a human cancer cell line, we took a dual whole-genome RNA sequencing approach that distinguishes total cellular mRNAs from nascent transcripts. Surprisingly, in ER-stressed human MDA-MB-231 breast cancer

cells, IRE1 α depleted not only canonical endomotif-containing RIDD substrates, but also multiple targets of “RIDD lacking endomotif” (RIDDLE). By isolating homotypic complexes of the human IRE1 α kinase-endoribonuclease module in monomeric, dimeric, or oligomeric form, we discovered that RIDD and RIDDLE reside in two distinct RNase modalities: endomotif-directed cleavage, minimally requiring IRE1 α dimers; and endomotif-independent cleavage, requiring phospho-oligomers. Indeed, an IRE1 α mutant that could form dimers but not oligomers selectively lost the RIDDLE modality. This mutant failed to rescue cancer-cell viability upon depletion of wildtype IRE1 α , demonstrating biological significance of IRE1 α oligomers and RIDDLE.

RESULTS

Integrated RNAseq and GROseq identify mRNA targets of IRE1 α -dependent decay

We reasoned that subtracting nascent-transcript alterations from global changes in mRNA abundance would help distinguish mRNA decay from diminished transcription. Accordingly, to examine mRNAs subject to IRE1-dependent decay, we applied two parallel RNA sequencing approaches: (1) classical RNAseq, which interrogates the steady-state transcriptome; and (2) global nuclear run-on sequencing (GROseq)⁵⁸, which interrogates the nascent transcriptome. We determined dependency on IRE1 α and ER stress by treating human MDA-MB-231 breast cancer cells, harboring homozygous wildtype (WT) or CRISPR/Cas9 knockout (KO) *IRE1 α* alleles¹⁴, with the classical ER stressor thapsigargin (Tg).

Most global-transcript levels did not change under these conditions (Fig. S1a). We identified 54 mRNAs as potential RIDD substrates: these displayed an IRE1 α -dependent, ER stress-induced decrease in abundance of at least 1.4-fold as measured by RNAseq, without corresponding declines in transcription as measured by GROseq (Table S1). We illustrate regulation of 8 of these mRNAs, including the known RIDD targets CD59 and DGAT2, as well as several novel ones, namely, TGOLN2, GBA, SNN, SIX2, TNFAIP18L1, and MFAP2 (Fig. 1a). By contrast, other mRNAs showed more complex behaviors: SCARA3 and PRICKLE2 mRNA levels declined both as measured by RNAseq and GROseq, exemplifying a class of mRNAs that decrease in abundance but may not be directly cleaved by IRE1, consistent with other results^{25,41}. CD59 and GBA showed down-regulation via both RIDD and diminished transcription; and MFAP2 was upregulated by ER stress while being suppressed via IRE1 α . Individual mRNAs displayed different decay rates, with some—such as TNFAIP8L1, SNN, and SIX2—showing a significant lag in depletion after Tg addition (Fig. 1a-b and Fig. S1b). Bioinformatic analysis suggested a notable frequency of hits in annotated categories of cell morphology, and cell death or survival (Table S2). Many lacked a signal peptide or anchor (Table S1), consistent with modulation of diverse cellular functions⁴⁵⁻⁴⁷.

As expected, GROseq detected over 300 mRNAs that displayed IRE1 α -dependent transcriptional upregulation by ER stress, enriched in gene-ontology of ER stress, ER-to-Golgi vesicle transport, IRE1-mediated UPR, N-linked glycosylation, and ERAD (Table S3). Several mRNAs represented known XBP1s transcriptional targets (Fig. S1c). GROseq also covered the genomic region encoding the XBP1u intron (Fig. S1d), providing further methodological validation.

IRE1 α displays two distinct endoribonuclease modalities

To explore molecular features that might govern RNase activity, we purified recombinant human IRE1 α kinase-endoribonuclease (IRE1-KR) proteins in unphosphorylated (0P) or fully phosphorylated (3P) states (Fig. S2a). IRE1-KR-0P efficiently cleaved an XBP1u-based T7 RNA polymerase transcript, at both of the known stem-loop endomotifs: processing produced ~500-nt and ~350-nt fragments, corresponding to the 5' and 3' exons; and the 26-nt intron (Fig. 2a, Fig. S2b,c). Scrambling either loop sequence prevented cleavage, while inserting 43-nt or 50-nt random sequences between the splice sites proportionally shifted the resulting bands (Fig. S2b,c). Thus, IRE1-KR-0P performs precise cleavage of XBP1u RNA at the two consensus sites, in keeping with other data^{22,29,31}.

Next, we examined the capacity of IRE1-KR-0P to process 8 of the 54 potential RIDD targets we identified, including 3 established and 5 newly uncovered ones (Fig. 2a). IRE1-KR-0P performed single-site cleavage of 4 of the RNAs, encoding BLOS1, CD59, DGAT2, and TGOLN2. Each of these contains an XBP1-like stem-loop endomotif, having the core consensus sequence CNGCAGN within a projected stem-loop secondary structure; the 5' and 3' fragments produced by IRE1-KR-0P for each RNA agreed in size with the location of the stem-loop endomotif (Fig. 2a and Table S4). Compared to XBP1u RNA, processing of the latter transcripts left more RNA substrate intact at the timepoint analyzed, indicating generally slower or less efficient reactions.

Scrambling the loop sequence of CD59 and DGAT2 prevented cleavage by IRE1-KR-0P (Fig. S2d), confirming its endomotif-restricted endoribonuclease activity.

Surprisingly, under the same reaction conditions, IRE1-KR-0P failed to cleave the other 4 RNAs, encoding TNFAIP18L1, SIX2, CFAP45, and MFAP2 (Fig. 2a). Resistance of these RNAs to cleavage correlated with their lack of a robust canonical stem-loop endomotif, as described below.

IRE1-KR-3P produced the same XBP1u RNA cleavage fragments as did IRE1-KR-0P; however, IRE1-KR-3P generated additional XBP1u fragments, visible as a faint smear (Fig. 2b), suggesting that it can catalyze further RNA decay. Uniquely, IRE1-KR-3P also cleaved into multiple fragments each of the 8 RNA substrates, including those that resisted cleavage by IRE1-KR-0P. Since these more promiscuous cleavages occur outside the endomotif, we categorize them as RIDDLE activity.

To ascertain dependence on IRE1 α , we included the IRE1 α RNase-directed inhibitor 4 μ 8c⁵⁹, which completely prevented RNA cleavage by both IRE1-KR-0P and IRE1-KR-3P (Fig. 2c). In contrast, the IRE1 α kinase-directed RNase inhibitor Compound 18^{15,60} blocked RNA decay, but not endomotif cleavage; and the kinase-based IRE1 α RNase activator CRUK-3⁶¹ endowed IRE1-KR-0P with an IRE1-KR-3P-like ability to cleave RNA in both modalities. Upon processing by IRE1-KR-3P, endomotif-mutated XBP1u and CD59 RNA substrates were more stable than WT counterparts (Fig. S2d), suggesting that endomotif-based cleavage can prime mRNA for RIDDLE, which then leads to further decay of the initial fragments. Kinetic analyses suggested faster endomotif cleavage by IRE1-KR-3P than IRE1-KR-0P, evident by swifter generation of

3' products from substrate RNAs (Fig. 2d and Fig S2e), and more rapid scission of a short synthetic hairpin endomotif (Fig. S2f). These results demonstrate that IRE1 α can switch between two different endoribonuclease modalities: (1) endomotif-restricted activity, which mediates both XBP1u intron excision and canonical RIDD; (2) endomotif-independent activity, which mediates RIDDLE, as well as further degradation after canonical endomotif recognition. IRE1-KR-0P supports the first modality but not the second, whereas IRE1-KR-3P conducts both.

Combining the data for the above 8 RNAs with empirical results for 4 additional targets, *i.e.*, PIGQ, BMP4, BCAM, and SNN (Fig. S2g), together with 29 earlier characterized human or mouse RIDD substrates^{27,43}, we developed a new computational algorithm, dubbed gRIDD, which accounts for all of these verified RIDD targets, and determines for any given mRNA the presence of any canonical stem-loop endomotif (see Supplemental Methods for a detailed description). This algorithm takes into account features that include: (1) conformity of the loop sequence to the consensus; (2) loop length and stem stability in context of the 55-60 flanking bases; (3) number of paired bases and any unpaired bases in the stem. To validate gRIDD, we analyzed a test-set of 4 additional transcripts from our screen. Two were found computationally to possess a canonical stem-loop endomotif, with either an exact match to (GBA) or a single nt variation from (WT1) the consensus loop sequence; accordingly, both IRE1-KR-0P and IRE1-KR-3P should cleave these latter RNAs. Another test RNA (CCDC69) has weak endomotif that fails gRIDD criteria, while a fourth one (AIM2) lacks an endomotif altogether; accordingly only IRE1-KR-3P should cleave these latter RNAs. Supporting gRIDD's accuracy, all test RNAs displayed the predicted cleavage

characteristics (Fig. S2h). Providing further validation, the known RIDD targets murine ANGPTL3⁴⁴, murine SUMO2, human SUMO3⁴², and human DR5⁴⁷ met the algorithm's criteria, whereas 10 mRNAs previously excluded from RIDD⁴¹ did not.

Of the 54 mRNAs we identified here (Table S4), gRIDD mapped 30 transcripts as possessing a canonical stem-loop endomotif (RIDD), including 22 with an exact and 8 with an acceptably variant, consensus loop sequence. In addition, gRIDD mapped 24 transcripts as lacking an endomotif (RIDDLE), including 15 with one or more sub-par stem-loop endomotif that failed the algorithm's criteria, and another 9 that had no discernable endomotif. We empirically confirmed RNAs from each of these subclasses.

RIDDLE is promiscuous in substrate recognition yet non-random

To test the uniformity of RNA decay by IRE1-KR-3P, we performed 3 independent RNA digestions of DGAT2 and TNFAIP8L1. Strikingly, IRE1-KR-3P generated the same banding pattern in all 3 cases, demonstrating that—although the processing appeared more promiscuous than endomotif-directed cleavage—it entailed consistent, non-random fragmentation (Fig. 3a). To search for underlying sequence requirements, we subjected TNFAIP8L1 RNA to cleavage by IRE1-KR-3P, resolved the products by agarose gel electrophoresis, and extracted them for Sanger sequencing. Overall, 60 of the 69 reads thus obtained indicated cleavage at GC sites, with infrequent cleavage at other sites (Fig. 3b). Alignment along the TNFAIP8L1 RNA indicated two relatively enriched cleavage locations, S1 (21/69) and S2 (11/69), both at GC sites (Fig. 3c). The sequences surrounding these two GC sites did not meet gRIDD's stem-loop endomotif

criteria. Regardless, replacing GC by TA at S1 or S2 abolished or diminished the corresponding cleavage product (Fig. 3d), confirming site selectivity. Likewise, analysis of DGAT2 RNA also revealed a preponderance of GC cleavages (34/61 reads, excluding the endomotif), and mutation of the most prevalent site precluded the corresponding product (Fig. S3 a-c). Thus, although RIDDLE is less restricted, it appears to favor GC sites.

Phospho-oligomeric state governs IRE1 α 's endoribonuclease modality

While activation of the IRE1 α RNase requires homodimerization, the importance of higher-order assembly is unclear^{56,62}. To directly investigate the role of such assembly, we covalently tethered IRE1-KR protomers by chemical crosslinking and studied their RNase modalities. Immunoblot analysis revealed that IRE1-KR-0P was primarily monomeric yet formed some detectable dimers in a concentration-dependent manner; in contrast, IRE1-KR-3P formed not only more prominent concentration-dependent dimers, but also oligomers consistent with relative masses of potential tetramers and hexamers (Fig. 4a). These results agree with other evidence that phosphorylation of IRE1 α promotes dimerization and stabilizes higher-order oligomerization^{22,52,63,64}.

IRE1-KR-3P retained RNase activity after crosslinking, evident by cleavage of XBP1u, DGAT2, and TNFAIP8L1 RNAs (Fig. S4a). To examine RNase modality, we resolved crosslinked IRE1-KR-3P complexes into monomers, dimers, and oligomers by native polyacrylamide gel electrophoresis (Fig. 4b), excised and eluted each complex, and reacted it with RNA substrate (Fig. 4c). Whereas IRE1-KR-3P monomers were

inactive as expected, dimers excised the XBP1u intron at both splice sites, and cleaved the DGAT2 RNA endomotif; however, they failed to further degrade DGAT2 RNA appreciably, nor did they cleave TNFAIP8L1 RNA. In contrast, IRE1-KR-3P oligomers cleaved XBP1u more completely, while substantially degrading both DGAT2 and TNFAIP8L1 RNAs. Upon prolonged incubation, IRE1-KR-3P oligomers achieved complete RNA degradation, as exemplified for DGAT2 RNA (Fig. S4b). Thus, whereas endomotif-directed cleavage minimally requires dimers, RIDDLE requires higher-order oligomerization. Supporting this conclusion, Compound 18, which selectively blocked endomotif-independent cleavage by IRE1-KR-3P (Fig. 2d), inhibited IRE1-KR-3P oligomerization but not dimerization (Fig. S4c). Moreover, CRUK-3, which enhanced endomotif-directed cleavage and endomotif-independent degradation (RIDDLE) by IRE1-KR-0P (Fig. 2d), congruently augmented IRE1-KR-0P oligomerization (Fig. S4c). Mutational analysis confirmed that at least two of the three phosphorylation sites within the kinase activation loop of IRE1 α (serine 724, 726, 729) were required for enhanced dimer formation, higher-order oligomerization, and the corresponding RNase modality. Of note, the triply phosphorylated protein showed a markedly better capacity to oligomerize and to perform RNA decay (Fig. S4d).

To seek further mechanistic insight, we screened for human IRE1 α mutations that might disrupt oligomerization, by testing several amino acid positions previously studied with yeast IRE1^{62,64}. One variant—R887A—proved particularly useful. Arginine 887 resides in the RNase domain within a helix loop element (HLE), shown to be important for binding and cleavage of *HAC1* mRNA in *S. cerevisiae*⁶⁴. As such, R887 does not stabilize IRE1's so-called back-to-back (B2B) dimer interface (Fig. 4d).

However, structural overlay of human B2B dimers (PDB ID: 6W3C) onto oligomeric *S. cerevisiae* IRE1 (PDB ID: 3FBV) places R887 at the interface of two B2B dimers within the projected human oligomer (Fig. 4e). Importantly, although IRE1-KR-R887A dimerized, it failed to form higher-order oligomers, regardless of phosphorylation (Fig. 4f). Compared to WT IRE1-KR-0P, unphosphorylated R887A performed endomotif-directed cleavage of DGAT2 and did not appreciably degrade DGAT2 or TNFAIP8L1 RNAs (Fig. 4g). Strikingly, phosphorylated IRE1-KR-R887A retained endomotif-directed DGAT2 cleavage, but unlike WT IRE1-KR-3P, it failed to degrade DGAT2 and TNFAIP8L1 RNAs. These loss-of-function results strongly validate the conclusion that RIDDLE depends on higher-order phospho-oligomers of IRE1 α .

Oligomer-deficient mutant IRE1 α fails to rescue cancer-cell viability

To extend the principles gleaned from our studies of IRE1-KR *in vitro* to full-length IRE1 α in cells, we devised a functional complementation strategy: We stably transfected shRNA-resistant cDNA expression plasmids encoding GFP-tagged⁵⁶ WT or IRE1 α -R887A into MDA-MB-231 cells harboring doxycycline (Dox)-inducible shRNAs against IRE1 α , and isolated GFP-positive transfectants by cell sorting. As expected, each ectopic protein expressed independent of Dox-inducible depletion of endogenous IRE1 α (Fig. 5a). The transgenic proteins migrated at a higher molecular mass, consistent with their GFP tagging, and showed elevated expression relative to endogenous IRE1 α . RT-qPCR analysis after a 72-hr Dox-induced depletion of intrinsic IRE1 α demonstrated that the ectopic WT and mutant variants supported a comparable fold-induction of XBP1s

upon ER stress (Fig 5b), suggesting similar capacity for endomotif-directed cleavage. To monitor RNase modality toward RIDD targets, we designed two specific RT-qPCR primer pairs for CD59 or TGOLN2: One encompasses the endomotif and therefore measures endomotif-directed cleavage (RIDD); the other covers the mRNA's 3' end and hence detects decay (RIDDLE; schematized in Fig. S5a). Although both WT and R887A mediated endomotif-directed cleavage of both CD59 and TGOLN2 mRNAs, only WT IRE1 α enabled complete RNA decay (Fig. 5b). Moreover, only WT IRE1 α —but not IRE1 α -R887A—depleted RIDDLE-targeted mRNAs TNFAIP8L1, SIX2, and SNN (Fig. 5b). We obtained similar data in HCC1806 cancer cells (Fig. S5b,c). Thus, IRE1 α displays the same two basic endoribonuclease modalities in cells as does its KR module *in vitro*.

The failure of IRE1 α -R887A to oligomerize and to acquire the corresponding RIDDLE modality afforded a unique opportunity to test the functional significance of the latter. To this end, we leveraged earlier work demonstrating that certain breast cancer cell lines depend on IRE1 α for viability during 3D growth¹⁴. In both cell lines, transgenic WT IRE1 α indeed rescued the loss of viability conferred by Dox-inducible knockdown of endogenous IRE1 α ; by contrast, IRE1 α -R887A failed comparably to restore cell survival (Fig. 5c and Fig. S5d). Together, these results link IRE1 α 's capacity to oligomerize and perform RIDDLE with its ability to support breast cancer cell survival during 3D growth.

DISCUSSION

Our studies conceptually advance the current mechanistic understanding of IRE1 α by shedding new light on the fascinating, yet puzzling, process of IRE1-dependent mRNA decay. Although in fly cells this process is thought to be relatively unrestricted by substrate sequence, in mammalian cells it was thought to require an XBP1-like stem-loop endomotif⁴⁰⁻⁴⁴. Despite some tantalizing clues that human IRE1 α may degrade a wider scope of mRNAs^{43,51}, to date this apparent disparity has not been deciphered. Our dual next-generation sequencing strategy, coupled with the discovery of a second basic endoribonuclease modality of IRE1 α and its coordinate phospho-oligomeric state, enabled several advances: (1) a refinement of the canonical stem-loop endomotif; (2) the development of a powerful and accurate algorithm to discern such endomotifs in prospective mRNAs; and perhaps more importantly, (3) the identification of RIDDLE as a specific, biologically significant activity of human IRE1 α .

As previously considered⁴⁰⁻⁴², a majority of RIDD substrates did not harbor secretion signals, and nor did the newly uncovered RIDDLE targets. Given that IRE1 is an ER-resident membrane protein, these observations raise the fundamental question of how it gains access to mRNAs that are not translated by membrane-bound ribosomes. Future work will be required to decipher whether such target mRNAs are delivered in a non-conventional manner—independent of a signal sequence—to the ER, perhaps to sites of IRE1 cluster formation. Alternatively, a fraction of IRE1 molecules

may become selectively proteolyzed to allow severed IRE1-KR domains to venture into the cytosol and act on non-membrane bound mRNAs^{65,66}.

Transcripts decayed through both the RIDD and RIDDLE modalities showed enrichment in functional categories such as cell morphology and cell death or survival, which may be linked to the cellular response to ER stress. For example, DGAT2 promotes triglyceride synthesis⁴⁴, while TNFAIP8L1 promotes apoptosis⁶⁷.

Previous reasoning divided IRE1's endoribonuclease modality into XBP1 processing *versus* RIDD. It was further thought that variation in target-sequence selectivity for RIDD substrates was probably due to inter-species diversity. Our findings establish a new conceptual organization (Fig. 5d) based on the two endoribonuclease modalities of human IRE1 α described here. The first modality, which minimally requires IRE1 α dimerization but can be performed also within phospho-oligomers (likely by the dimer-building blocks from which it is assembled), carries out endomotif-specific RNA cleavage; the second, which strictly requires phospho-oligomerization, conducts more promiscuous endoribonuclease activity. The first modality enables both the dual cleavage of XBP1u and initial single-site cleavage of RIDD targets containing a robust XBP1-like stem-loop endomotif. The second modality mediates RIDDLE, which digests RNA substrates that either have a sub-optimal stem-loop endomotif, or lack one altogether. Importantly, RIDDLE also degrades canonical endomotif-cleaved RIDD substrates. Our detailed studies with DGAT2 and TNFAIP18L1 RNA suggest that RIDDLE favors GC sites; future studies should examine additional RIDDLE substrates to determine whether such sites are universal. Our new conceptualization aligns IRE1 α multimer assembly with endoribonuclease modality. Phosphorylated oligomers

performed RNase cleavage with better efficiency than dimers, pointing to a “rheostatic” nature of IRE1 α activation, as previously suggested^{34,35}. Accordingly, stronger ER stress could drive higher levels of IRE1 α phospho-oligomerization, increasing catalytic efficiency for both XBP1s generation and RNA decay.

Mutations that impaired phosphorylation and/or oligomerization confirmed and reinforced the requirement of distinct oligomeric states for the two basic RNase modes of IRE1 α . Each phosphorylation site appeared similarly important for efficient oligomerization as well as for RNA decay, with triple phosphorylation leading to strongest activity. The data in breast cancer cells differs from B cells, wherein S729 proved more critical for RIDD⁵⁰. Regardless, the R887A mutation, which prevented IRE1-KR oligomerization independent of phosphorylation state, demonstrated the critical importance of oligomers for RIDDLE-mediated RNA decay. Residing on human IRE1 α B2B dimers, R887 may enable oligomer stabilization via double salt bridging with E876 residues on opposing B2B dimers. Supporting this notion, overlay of the human IRE1 α dimer onto the yeast oligomer places E876 within just 7 Å from R887 (Fig. 4d).

RNase activity of IRE1 α may vary with substrate length. It is possible that dual XBP1u processing occurs more efficiently within phospho-IRE1 α tetramers, which bind simultaneously to the two stem-loop endomotifs. Similarly, it is conceivable that for canonical RIDD targets, one IRE1 α dimer binds to the stem-loop endomotif, while additional associated dimers within an oligomer cleave the transcript at additional locations. Future structural work is needed to explore oligomeric mammalian IRE1 α alone and in complex with different RNAs. In addition, it will be important to investigate how the RNase modalities unraveled here apply to IRE1 from different species and

model organisms. Emerging data for yeast IRE1 indicates that the positioning of the RNase domains within dimers regulates substrate recognition (W.L., P.W., submitted).

Intriguingly, even the initial products of XBP1u processing underwent detectable degradation by IRE1-KR-3P, consistent with the previously proposed concept that XBP1 mRNA splicing involves kinetic competition between exon ligation and mRNA degradation⁵¹. This earlier study, however, identified components of the NO-GO and cytosolic exosome machineries as the exonucleases mediating further decay from the primary cut sites. Importantly, although additional endonucleotic cleavages near ribosomes stalled on severed mRNA were uncovered, the nuclease(s) responsible for these cuts remained elusive. It remains to be determined whether IRE1 plays a direct part in such clearing mechanisms by which cells rid themselves of defective mRNA. In the cellular environment, additional factors, including the Sec61 translocon⁶⁸, or RNA-binding proteins such as Pumilio (Cairrao et al, co-submitted), could also help shield processed XBP1u against further decay and thereby permit exon ligation by RtcB⁶⁹.

In conclusion, our discovery and functional characterization of two enzymatic modalities of IRE1 α RNase advance the present conceptual framework for investigating how IRE1 operates across different eukaryotes. Together with the demonstration that RIDDLE is important for cancer-cell survival, our mechanistic dissection carries important implications for biological understanding of the UPR and for harnessing IRE1 α as a potential therapeutic target.

ACKNOWLEDGEMENTS

We thank Ben Haley for gDNA design, Maria Lorenzo for protein purification, Maureen Beresini, Ira Mellman, and members of the Ashkenazi lab at Genentech and the Walter lab at UCSF for helpful discussions.

FIGURE LEGENDS

Figure 1. Integrative RNAseq and GROseq analyses identify human RIDD and RIDDLE targets. (a) Mean RPKM values for various examples of IRE1 α RNase targets from the RNAseq and GROseq datasets in WT and IRE1 α KO MDA-MB-231 cells before and after ER-stress induction by Tg (100 nM). (b) Kinetic RT-qPCRs analysis of CD59 and TNFAIP8L1 transcripts in WT and IRE1 KO MDA-MB-231 cells, before and after ER-stress induction by Tg (100 nM) for 2 and 8 hours.

Figure S1. Integrative RNAseq and GROseq analyses identify human RIDD and RIDDLE targets. (a) IRE1-dependent Log₂ fold change in mRNA levels after Tg treatment of MDA-MB-231 cells, as determined by RNAseq. (b) Kinetic RT-qPCRs analysis of gene transcripts identified through integrative RNAseq and GROseq analysis in *IRE1 α* WT and KO MDA-MB-231 cells. (c) Fold enrichment after ER stress induction by Tg for specific XBP1s target genes in IRE1 α WT and KO cells, as determined from the RNAseq and GROseq datasets. (d) Read coverage around the spliced XBP1 genomic region (part of exon 4) in all various datasets.

Table S1. Summary of IRE1 dependent down-regulated targets in MDA-MB-231 cells. mRNA transcripts down-regulated upon ER stress in an IRE1 α -dependent and transcription-independent manner. The percentage of IRE1 α -dependent down-regulation upon Tg treatment measured by RNAseq is represented in column 3. Fold depletion of total RNA (RNAseq Log₂(FC)WT) over transcriptional down-regulation (GROseq Log₂(FC)WT) is indicated in column 4. Analysis for the presence of a signal peptide (Type I) or signal anchor (Type II) sequence is indicated in the last column.

Table S2. Ingenuity Pathway Analysis (IPA) of IRE1 α 's mRNA decay targets in MDA-MB-231 cells. Top 5 enriched pathways in the Molecular and Cellular Functions category according to the IPA software, along with their p-value range and the number of targets in that group.

Table S3. GO term analysis of mRNA targets up-regulated in IRE1 α -dependent manner after Tg treatment in MDA-MB-231 cells based on the GROseq dataset. Most enriched GO terms in the Biological process category, along with their p-value and the number of targets in that group.

Figure 2. Phosphorylation state of IRE1 α affects RNase modality. In vitro-generated T7-RNAs were incubated with purified recombinant IRE1 α protein (residues G547-L977) comprising the kinase-endoribonuclease module (IRE1-KR), in non-phosphorylated (KR-0P) (**a**) or fully phosphorylated (KR-3P) (**b**) form, and RNA products were analyzed by agarose gel electrophoresis. Where shown, solid arrows indicate RNA substrates; open arrows mark RNA cleavage products, representing the 5' and 3' fragments around the cleavage site. Specific RNA endomotifs are depicted on top for respective targets. (**c**) KR-0P and KR-3P digestions of XBP1, DGAT2, and TNFAIP8L1 transcripts in the presence of the IRE1 α RNase inhibitor 4 μ 8C, the IRE1 α kinase-based RNase inhibitor Compound 18 (Cpd-18), or the IRE1 α kinase-based RNase activator Compound 3 (CRUK-3). (**d**) KR-3P digestion of XBP1u and DGAT2 mRNA at shorter duration. Intensities of the 3' RNA fragment were quantified for XBP1u and DGAT2 using GelQuantNET from the RNA digestion agarose gels shown above.

Figure S2. Phosphorylation state of IRE1 α affects RNase modality. (a) Each IRE1-KR protein was purified by size exclusion chromatography and its identity and phosphorylation state were verified by liquid chromatography-mass spectrometry (LC-MS). Pre-existing phosphates were removed by treatment with λ -phosphatase (KR-0P), or full autophosphorylation was allowed in the presence of ATP (KR-3P). (b) KR-0P digestion of XBP1u transcript variants: WT; loop motif 1 scrambled (S1); loop motif 2 scrambled (S2); loop motif 1 and 2 scrambled (S1+2); intron with 43-nt (X43) or 50-nt (X50) random sequence inserted. Schematic illustration of each variant is depicted on the right side of the gel aligned with corresponding products. (c) KR-0P digestion of XBP1u variants at higher concentrations to visualize resulting spliced fragments (highlighted in the red boxes with their respective expected size). (d) KR-0P digestions of CD59 and DGAT2 RNA transcripts in WT and scrambled endomotif mutant (MT) version. (e) KR-3P digestions of WT or MT (scrambled endomotif) versions of XBP1u, DGAT2, and CD59 RNAs were performed for the indicated time and analyzed as above. (f) Michaelis-Menten kinetics for RNase activity of KR 0P (blue) and KR-3P (red). Each KR protein (10 nM) was incubated for 1 hr at room temperature with quenched fluorescein-conjugated RNA substrate at varying concentrations. As the substrate is cleaved by IRE1 α RNase, FAM fluorescence is emitted and can be measured at regular intervals during the incubation time (see methods section for details). Velocity was measured as Relative Fluorescent Units (RFU)/sec and is shown in the graph as a function of RNA substrate concentration. Background signal of the RNA-only sample is depicted in gray. Kinetic parameters (K_m and V_{max}) of the reaction were calculated for both enzymes using Prism and are reported on the graph. (g,h) T7 RNAs for PIGQ,

BMP4, BCAM, and SNN (**g**); or GBA, WT1, CCDC69, and AIM2 (**f**) were incubated with KR-0P and KR-3P and analyzed.

Table S4. Canonical stem-loop endomotif analysis of RIDD targets from Table S1 using the gRIDD algorithm. mRNA transcripts down-regulated upon ER stress in an IRE1 α -dependent and transcription-independent manner were analyzed for the presence and robustness of a canonical XBP1-like stem-loop endomotif, using a newly developed algorithm termed gRIDD (see supplementary methods for detailed description of gRIDD). Columns 1 and 2 indicate gene names and transcript references. Column 3 indicates mRNA nucleotide position of the G within the GC cleavage site. Column 4 illustrates the loop sequence and stem topology of the endomotif, where a parenthesis indicates a nucleotide that is paired with a complementary one on the opposite leg of the stem, and a dot indicates an unpaired nucleotide. Lowercase letters indicate variation to the consensus loop sequence at position 2 or 5, indicated in column 5 as Var2 and Var5 respectively. Column 6 indicates the number of base pairs at the stem. Column 7 indicates the free energy (kcal/mol) for the stem-loop structure represented in column 4. Columns 8 and 9 indicate failure to meet gRIDD criteria due to excessive loop-length (FL) and/or disrupted base pairing at the stem (FS). Column 10 indicates empirical results for cleavage by IRE1-KR-0P (0P) or IRE1-KR-3P (3P). All transcripts cleaved by IRE1-KR-0P were also cleaved by IRE1-KR-3P. In each case, the best possible stem-loop endomotif is displayed. The first and second categories include mRNAs with stem-loop endomotifs that meet gRIDD criteria (RIDD modality). The third and fourth categories include mRNAs wherein the best possible endomotif

nevertheless fails to meet gRIDD criteria or no stem-loop endomotif is found (RIDDLE modality). Within each category, transcripts are ranked by free energy.

Figure 3. RIDDLE is relatively unrestricted by substrate sequence but non-

random. (a) Comparative KR-3P digestion of DGAT2 and TNFAIP8L1 transcripts performed in three independent experiments. (b) Amount of RNA fragments sequenced whose 3' end leads to the cleaved nt pair designated on the x axis. The first nt in the pair represents the last sequenced nt from the RNA fragment, while the second shows the subsequent base in the RNA sequence. Inset: red box indicates the portion of the gel that was extracted for Sanger sequencing. (c) Mapping of the last base pair (3' end) from each individual RNA fragment sequenced within the TNFAIP8L1 mRNA. Red bars indicate cleavage sites between a GC nt pair. (d) RNA digestions of WT TNFAIP8L1 and TNFAIP8L1 mutated at locations S1 and S2. The red arrows indicate change in banding pattern as compared to WT.

Figure S3. RIDDLE is relatively unrestricted but non-random. (a) Amount of RNA fragments sequenced whose 3' end leads to the cleaved nt pair designated on the x axis. The first nucleotide in the pair represents the last sequenced nucleotide from the RNA fragment, while the second nucleotide shows the following base in the RNA sequence. Inset: red box indicates the portion of the gel that was extracted for subsequent sequencing. (b) Mapping of the last base pair (3' end) from each individual RNA fragment sequenced within the DGAT2 mRNA. Red bars indicate cleavage sites between a GC nt pair. (c) RNA digestions of WT DGAT2 and DGAT2 mutated at location S1 or at the stem-loop endomotif (EM). The red arrows indicate change in banding pattern as compared to WT.

Figure 4. Phospho-oligomeric state governs IRE1 α 's RNase modality. (a) DSS crosslinking of IRE1-KR-0P and IRE1-KR-3P at various concentrations. (All lanes have the same final amount of protein loaded.) (b) Cartoon depicting the procedure to extract KR-3P fractions before incubation with T7 RNAs. (c) Digestion of XBP1u, DGAT2, and TNFAIP8L1 RNA by isolated fractions of IRE1-KR-3P: M, monomer; D, dimer; and O, oligomer. (d) WT structure of IRE1 α dimer with the residues of interest highlighted: alignment of yeast B2B IRE1 α (PDB ID: 3FBV, green) and human B2B IRE1 α (PDB ID: 6W3C, magenta). (e) Alignment of yeast oligomeric IRE1 α (PDB ID: 3FBV) and two dimers of human IRE1 α (PDB ID: 6W3C). Inset: R887-E876 spatial arrangement based on the alignment. (f) DSS crosslinking of purified recombinant IRE1-KR-3P WT and R887A protein. (g) Digestion of DGAT2 and TNFAIP8L1 RNA by IRE1-KR-3P WT and R887A.

Figure S4. Phospho-oligomeric state governs IRE1 α 's RNase modality. (a) IRE1-KR-3P digestion of XBP1u, DGAT2, and TNFAIP8L1 RNA immediately after DSS crosslinking and before fractionation of the protein. (b) Digestion of DGAT2 RNA by crosslinked IRE1-KR-3P at the indicated incubation time after protein fractionation. (c) DSS crosslinking of IRE1-KR in the presence of Cpd-18 or CRUK-3. (d) DSS crosslinking of IRE1-KR WT or IRE1-KR mutated at the indicated activation-loop phosphorylation sites, and corresponding digestion of XBP1u, DGAT2, and TNFAIP8L1 RNA. Intensities of RNA fragments for each variant were quantified using GelQuantNET, as depicted on the right side of the gel.

Figure 5. Cellular IRE1 α displays the same fundamental RNase modalities and requires RIDDLE to support viability. (a) Western blot analysis of endogenous and

ectopic IRE1 α variant expression in MDA-MB-231 cells harboring Dox-inducible IRE1 α shRNA stably transfected with transgenic WT or R887A mutant versions of IRE1 α -GFP. **(b)** RT-qPCR analysis of IRE1 α RNase targets CD59, TGOLN2 (RIDD), and TNFAIP8L1, SNN, and SIX2 (RIDDLE). *: Ct values for XBP1 in sample shIRE1 cl.1 prior to Tg treatment were >34, precluding ratio calculations. **(c)** Analysis of cell viability by Cell-Titer Glo after Dox treatment for 7 days on standard flat bottom (2-D) or Ultra-Low Attachment (ULA) plates (3-D growth). **(d)** Model depicting IRE1 α 's principal modes of endoribonuclease function and their underlying phospho-oligomeric states during ER stress.

Figure S5. Cellular IRE1 α displays the same two fundamental RNase modalities and requires RIDDLE to support viability. **(a)** Cartoon depicting the location of the primer pairs used for RT-qPCR analysis of endomotif-directed cleavage vs. RIDDLE. **(b)** Western blot analysis of endogenous and ectopic IRE1 α variant expression in HCC1806 cells harboring Dox-inducible IRE1 α shRNA that were stably transfected with transgenic WT or R887A mutant versions of IRE1 α -GFP. **(b)** RT-qPCR analysis of IRE1 α RNase targets as described for Fig. 5.

MATERIALS AND METHODS:

Cell culture and experimental reagents:

MDA-MB-231 cells were all obtained from ATCC, authenticated by short tandem repeat (STR) profiles, and tested to ensure mycoplasma free within 3 months of use. All cell lines were cultured in RPMI1640 media supplemented with 10% (v/v) fetal bovine serum (FBS, Sigma), 2 mM glutaMAX (Gibco) and 100 U/ml penicillin plus 100 µg/ml streptomycin (Gibco).

Thapsigargin (Sigma) was used at a concentration of 100 nM. Compound 4µ8C and Compound 18 were dissolved in DMSO for cellular experiments and used at the indicated concentrations. Antibodies (Abs) for IRE1α (#3294), and GAPDH (#8884) are from Cell Signaling Technology. Secondary antibodies (rabbit #711-035-152 and mouse #715-035-150) were from Jackson ImmunoResearch Laboratories.

CRISPR/Cas9 knockout: Guide RNA sequences and technique:

MDA-MB-231 *IRE1α* KO cells were generated using CRISPR by co-transfecting a Cas9 containing plasmid, pRK-TK-Neo-Cas9, with a pair of IRE1 targeting gRNAs (see below) cloned into a pLKO vector. Transfection was done using Lipofectamine 3000 according to manufacturer protocol, and transformants were selected by PCR on genomic DNA for the detection of deletions. Correct clones were then sequenced.

IRE1α KO cl.1-2 gRNA pair: CTTGTTGTTTGTGTCAACGC &
TCTTGCTTCCAAGCGTATAC.

RNAseq / GROseq:

Both RNAseq and GROseq were performed on WT and *IRE1α* KO MDA-MB-231 cells.

For each RNAseq and GROseq there were four experimental conditions (WT and *IRE1α* KO, treated with Tg or vehicle control (DMSO) for 8 hr with three biological replicates (n=3) for each condition.

For RNAseq, RNA was extracted using the RNeasy kit (Qiagen #74104) performing on-column DNA digestion for 15 min. The concentration of RNA samples was determined using NanoDrop 8000 (Thermo Scientific) and the integrity of RNA was analyzed by Fragment Analyzer (Advanced Analytical Technologies). Approximately 500 ng of total RNA was used as input for library preparation using TruSeq RNA Sample Preparation Kit v2 (Illumina).

For GROseq, cells were pre-treated with 5-ethynyl uridine (EU) for 30 min prior to nuclei fractionation using Sigma kit (#NUC101) followed by Invitrogen Click-iT™ Nascent RNA Capture Kit protocol for nascent transcript extraction (#C10365). RNA was then extracted using the RNeasy kit (Qiagen #74104) performing on-column DNA digestion for 15min and was subsequently reverse transcribed with Superscript VILO IV Master Mix from Invitrogen. Libraries were prepared following the protocol from NEBNext® Ultra™ II RNA Library Prep Kit for Illumina® (NEB #E7770S) and indexes (NEB #E7335S and #E7500S).

The size of the libraries for both RNAseq and GROseq was confirmed using 4200 TapeStation and High Sensitivity D1K screen tape (Agilent Technologies) and their concentration was determined by qPCR based method using Library quantification kit (KAPA). The libraries were multiplexed and then sequenced on Illumina HiSeq2500 (Illumina) to generate 30M of single end 50 base pair reads.

RNAseq-GROseq combined analysis of IRE1 α specific targets:

To identify IRE1 α specific RIDD targets we compared genes' differential expression in WT *versus* KO cells after 8 h Tg treatment: Log₂ fold change (Log₂(FC)), average expression, *p*-values, and false discovery rate (fdr) values were calculated for every protein-coding genes comparing the starting DMSO time point with 8 h after Tg treatment in WT and *IRE1 α* KO conditions for both RNAseq and GROseq datasets. Log₂(FC) in the RNAseq WT dataset for which the *p*-value and the fdr value were above 0.05 were removed. Log₂(FC) difference between the RNAseq WT and *IRE1 α* KO (Log₂(KO-WT)) datasets falling below 0.5 were removed, and genes with average expression values below 1 were also removed. Finally, Log₂(FC) differences between the RNAseq and GROseq WT (Log₂(WT_{rna}-WT_{gro})) falling below -0.3 were removed. The resulting gene list is 55 entries long.

Signal sequence analysis:

For each mRNA transcript selected as the representative candidate for a gene, we determined the corresponding protein sequence by running GMAP (version 2019-12-01)⁷⁰ by aligning the sequence to itself using the -g flag and extracting the full-length protein translation with the flags "-P -F". We then ran the program signalp (version 3.0)⁷¹ on the protein sequence with the flag "-t euk", which yielded a signal sequence prediction and probabilities for the signal peptide, signal anchor, and cleavage site. Each mRNA was also checked in Uniprot for additional verification.

RT-qPCRs:

RNA was extracted using the RNeasy Plus kit (Qiagen #74134). Equal amounts of RNA were reverse transcribed and amplified using the TaqMan™ RNA-to-CT™ 1-Step Kit (Applied Biosystems #4392938) on the ABI QuantStudio 7 Flex Real-Time PCR System. The delta-delta C_T values were calculated by relating each individual C_T value to its internal GAPDH control. Taqman primers for XBP1u (#Hs02856596_m1), XBP1s (#Hs03929085_g1), DGAT2 (#Hs01045913_m1), BLOC1S1 (#Hs00155241_m1), CD59 (#Hs00174141_m1), and TNFAIP8L1 (#Hs00537038_m1), and GAPDH (#Hs02758991_g1) were from Life Technology. Additional primer pairs used for qPCR from cell rescue experiments were ordered from IDT: TNFAIP8L1 (#Hs.PT.58.39992641), SNN (#Hs.PT.58.28146300), SIX2 (#Hs.PT.58.40614621),

GAPDH (#Hs.PT.39a.22214836), and custom-designed:

CD59	Endomotif	f:GCAGTCAGCGTTGGGTTAG	r:CTCGTCCTGGCTGTCTTCT
	3' end	f:GCCTGCAGTGCTACAACT	r:CAATGCTCAAACCTCCAACACT
TGOLN2	Endomotif	f:GCCTCCGCACTCGACTT	r:GCCTGGAGGCTCTACCAA
	3' end	f:TCACAACAAGCGGAAGATCA	r:AGAGGAATATACCATTCTGTTAGGAC

T7 RNA constructs:

We prepared T7 RNA transcripts from cDNA templates chosen based upon functional relevance coupled with optimal length for the ribonucleolytic reaction (~0.5 to 2 kb).

cDNA constructs encoding XBP1 (#HG10751-UT), DGAT2 (#HG14114-G), CD59 (#HG12474-UT), TGOLN2 (#HG17252-UT), SIX2 (#HG21116-UT), CFAP45 (#HG22377-UT), MFAP2 (#HG16644-UT), PIGQ (#HG22757-UT), BMP4 (#HG10609-UT), BCAM (#HG10238-UT), SNN (#HG23279-U), GBA (#HG12038-UT), WT1 (#HG12282-UT), CCDC69 (#HG27177-U), AIM2(#HG11654-UT) were from Sino Biological, and BLOC1S1 (#RC224412), TNFAIP8L1 (#RC203912) from Origene. cDNA was amplified using T7 forward primers, and subsequently in-vitro transcribed using HiScribe™ T7 Quick High Yield RNA Synthesis Kit from NEB (#E2050S).

T7 RNA mutations were engineered using overlap PCR followed by restriction digests, and the final fragments were purified from agarose gel (Zymoclean Gel DNA Recovery kit #D4001).

Protein purification and separation of phosphorylated IRE1 α fractions:

IRE1 α KR 0P and 3P were produced by Accelagen and in-house: IRE1 α KR (G547-L977) was expressed as N-terminal His₆-tagged fusion proteins in SF9 cells with a TEV protease cleavage site from an intracellular BEVS expression vector. Cell pellet was resuspended in lysis buffer containing 50 mM HEPES pH 8.0, 300 mM NaCl, 10% glycerol, 1 mM MgCl₂, 1:1000 benzonase, EDTA-free PI tablets (Roche), 1mM TCEP, and 5mM imidazole. Sample was lysed by sonication, centrifuged at 14,000rpm for 45min, and the supernatant filtered through a 0.8 μ m Nalgene filter. Cleared supernatant was bound to Ni-NTA Superflow beads (Qiagen) by gravity filtration. Beads were washed in lysis buffer supplemented with 15 mM imidazole, followed by protein elution in lysis buffer containing 300 mM imidazole. The eluate was incubated with TEV protease overnight at 4°C. The sample of IRE1 α KR protein was diluted 1:10 in 50 mM HEPES pH 7.5, 50 mM NaCl, 1mM TCEP and then loaded onto a 5mL pre-packed Q-HP column (GE-Healthcare). Separation of IRE1 α KR unphosphorylated and phosphorylated was achieved by eluting the protein with a very shallow gradient (50-300 mM NaCl over 70CV). Fully phosphorylated fraction (MW+240 by LC-MS) was collected separately, while the rest of the protein fractions were consolidated and incubated with Lambda phosphatase for one hour at room temperature. Dephosphorylation was confirmed by LC-MS. Unphosphorylated and phosphorylated samples were then concentrated and loaded separately onto a HiLoad 16/600 Superdex 200 SEC column (GE Healthcare) equilibrated in 25 mM HEPES pH 7.5, 250 mM NaCl, 1 mM TCEP, 10% glycerol. IRE1 α eluted as a monomer.

Mutants S724A, S726A, S729A, S724A-S726A, S724A-S729A, S726A-S729A, and R887A were produced in-house following the same procedure described above.

Phosphorylation site mapping was performed by LC-MS/MS analysis following protease digestion:

IRE1 α KR	% phosphorylation		
	S724	S726	S729
WT 3P	82	Yes*	52
S724A 2P	-	>90	>90
S726A 2P	90	-	71
S729A 2P	82	Yes*	-
S724A-S726A 1P	-	-	97
S726A-S729A 1P	89	-	-
S724A-S729A 1P	-	Yes*	-

Yes* denotes observed S726 phosphorylation for which quantification was not possible due to the presence of a miscleaved peptide containing phosphorylated S726.

Phosphorylation of IRE1 α KR and activation loop mutants:

IRE1 α KR S/A and R887A mutants were allowed to autophosphorylate in the presence of 2 mM ATP and 10 mM MgCl₂ for one hour at room temperature. Sample was purified from ADP by size-exclusion chromatography (SEC).

Mutants S726A-S729A, was not capable to autophosphorylate and was instead incubated with pIRE1 α LKR (Linker-Kinase-RNase, residues Q470-L977) at 1:40 w/w, 2 mM ATP and 20 mM MgCl₂. Final phosphorylated proteins were purified from pIRE1 α LKR and residual nucleotides by SEC.

RNA cleavage assay:

1 μ g of T7 RNA generated was digested at room temperature by 1 μ g of human IRE1 α KR recombinant protein (~0.8 μ M) for 15 min in RNA cleavage buffer (HEPES pH7.5 20 mM; K acetate 50 mM; Mg acetate 1 mM; TritonX-100 0.05% (v/v)). The total volume of the reaction is 25 μ l. The digestion was then complemented by an equal volume of formamide and heated up at 70°C for 10 min to linearize the RNA. After linearization, the mixture was immediately placed on ice for 5 min, and then 20 μ l was run on 3% agarose gel at 160V for 1 hour at 4°C. If inhibitors were used, they were incubated with the RNA for 40 min on ice prior to RNA digestion. Gels were visualized on either a BioRad Molecular Imager ChemiDoc ZRS+ or Azure Biosystems c600.

RNA fragment sequencing:

2 µg of T7 RNA (TNFAIP8L1, DGAT2) is used for digestion by human IRE1 α KR-3P as described above. RNA bands are extracted from gel using Zymoclean Gel RNA Recovery Kit (Zymo Research #R1011). Next, the RNA extracted was ligated using RtcB ligase (NEB # M0458S) to a 3'-adapter oligo custom designed and ordered from IDT (caagcagaagacggcatatcgatCGTGAT), following manual protocol. Ligated RNA was then reverse transcribed using SuperScript™ IV First-Strand Synthesis System (Invitrogen #18091050) and a 3'-adapter specific primer (ATCACGatctcgatgccg). cDNA was then amplified using DGAT2 (gggGCATGCATGAAGACCCTCATAGCCG) or TNFAIP8L1 (gggGCATGCATGGACACCTTCAGCACCAAG) specific forward primer containing an SphI restriction enzyme site, and a common reverse primer containing a EcoRI restriction enzyme site (gggGAATTCATCACGatctcgatgccg). PCR product were subsequently digested by SphI and EcoRI prior cloning into a pGEM®-T Easy Vector (Promega #A1360). Then, resulting plasmids are transfected into competent cells (Zymo *Mix & Go!* Competent Cells Zymo 10B #T3019), plated on a 10 cm dish and left at 37°C overnight. The following day, individual colonies are picked and grown onto 96 wells plates, designed for bacterial growth (Thomson Instrument Company #951657), overnight. Finally, DNA is extracted from individual wells using Zyppy-96 Well Plasmid Miniprep Kit (Zymo Research #D4042) and sent for SANGER sequencing.

RNase activity assay (kinetic fluorescence):

A 5'-Carboxyfluorescein (FAM)-and 3'-Black Hole Quencher (BHQ)-labeled single stem-loop mini-substrate containing XBP1 sequence (5'FAM-CAUGUCCGCAGCGCAUG-3'BHQ) was used as substrate for cleavage by IRE1 α KR (G547-L977) in 20 mM HEPES pH 7.5, 50 mM potassium acetate, 1 mM magnesium acetate, 1 mM dithiothreitol, 0.05% v/v TritonX-100. 10 nM of protein was incubated with varying concentrations of RNA substrate (2-fold dilution series from 3000 nM to 5.86 nM). RNA cleavage was measured kinetically over an hour at room temperature as an increase in fluorescence. The final reaction was carried out in 20 μ L in 384-well plates. Samples were run in duplicate. Velocity of the reaction was measured as the slope of the linearly increasing fluorescence signal over time as Relative Fluorescence Units (RFU)/sec and plotted as a function of RNA substrate concentration. Michaelis-Menten kinetics were fit using Prism 1.7 and resulting Vmax and Km constant were reported.

Immunoblot analysis:

Cells were lysed in 1x RIPA buffer (Millipore) supplemented with fresh protease and phosphatase inhibitors (Invitrogen #78440), cleared by centrifugation at 13,000 rpm for 15 min, and analyzed by BCA protein assay (ThermoFisher Scientific #23227). Equal protein amounts were loaded, separated by SDS-PAGE, electrotransferred to nitrocellulose membranes using the iBLOT2 system (Invitrogen), and blocked in 5% nonfat milk solution for 30 min. Membranes were probed with the following antibodies:

IRE1 α , XBP1s, or GAPDH. Signal was detected using appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies. All primary antibodies were used at 1:000 dilution and overnight hybridization at 4°C, followed by a two-hour incubation with horseradish peroxidase (HRP)-conjugated secondary antibodies at 1:10,000 dilution.

Crosslinking Assay:

1 μ g of IRE1-KR recombinant protein was crosslinked in 25 μ l final volume of RNA cleavage buffer containing 1 μ l of disuccinimidyl suberate (DSS, Thermo Fisher Scientific) crosslinker at 6.25 mM (final concentration is 250 μ M) for 1 h on ice. For experiments recurring inhibitor and activator compounds, IRE1 α KR and the small molecule compound were first pre-incubated together on ice for 40min. The reaction was quenched using 1 μ l of a pH 7.5, 1M TRIS solution for 15 min on ice. The reaction was then diluted in 500 μ l of RNA cleavage buffer and 13 μ l of it was used to run on SDS-PAGE gel (corresponding to ~25 μ g of protein. The gel was run at 100V for almost 3 h then electro-transferred to nitrocellulose membranes using the iBLOT2 system (Invitrogen), and blocked in 5% nonfat milk solution. Finally, it was incubated overnight at 4°C with an IRE1 α antibody (Cell Signaling, #3294S) at 1:1000 dilution, followed by a two-hour incubation with horseradish peroxidase (HRP)-conjugated secondary antibodies at 1:10,000 dilution.

Gel fractionation:

100 µg of IRE1-KR-3P was crosslinked with DSS for 30 min on ice. The reaction was then loaded on Invitrogen 4-16% NativePAGE gel at 4°C for 4 h at 100V. Subsequently, the gel was cut in pieces at locations corresponding to monomer, dimer, and oligomer fractions. Gel fractions were then put in 100 µl of RNA cleavage buffer containing 4 µg of the T7 RNA transcript to digest overnight at 4°C. Finally, 10 µl of the reaction was used and run on a 3% agarose gel for visualization.

Cell IRE1 Rescue:

MDAMB231 or HCC1806 shIRE1 α cell lines were transfected with a 2 kb IRE1 α promoter-driven - shIRE1 α resistant - GFP/His tagged IRE1 α WT or R887A mutant - Neomycin resistant construct, using Mirus TransIT-X2 delivery system on 6 well plates. After 24h cells were transferred to individual T75 flasks for 4 days. Media was changed and cells were selected using Geneticin at 1.5mg/ml final for roughly 10 days, then FACS sorted for GFP positive cells.

Viability Assay:

4000 cells were plated in 4 replicates on 96-well Corning plates either standard flat clear-bottom or ULA (#7007). At plating, cells were treated with a 0.4 µg/ml Doxycycline (Clonetechn) final concentration in 200 µl total volume. 7 days later, 100 µl of media was taken out very carefully from each plates, not disturbing the spheroids from the ULA

plate. Cell viability was then assessed by CellTiter-Glo 3D, adding 100 µl of buffer (Promega #G9683) to each well and pipetting up and down a few times, and measured in a luminescence reader (Envision; PerkinElmer). The data depicted as Relative viability after Dox treatment is calculated from the means of quadruplicate samples, wherein viability of Dox treated cells is divided by that of untreated cells (ratio) and normalized to 2D mean viability.

REFERENCES

1. Ron, D. & Walter, P. Signal integration in the endoplasmic reticulum unfolded protein response. *Nat Rev Mol Cell Biol* **8**, 519-529 (2007).
2. Schroder, M. & Kaufman, R.J. The mammalian unfolded protein response. *Annu Rev Biochem* **74**, 739-789 (2005).
3. Walter, P. & Ron, D. The unfolded protein response: from stress pathway to homeostatic regulation. *Science* **334**, 1081-1086 (2011).
4. Hetz, C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. *Nat Rev Mol Cell Biol* **13**, 89-102 (2012).
5. Shore, G.C., Papa, F.R. & Oakes, S.A. Signaling cell death from the endoplasmic reticulum stress response. *Curr Opin Cell Biol* **23**, 143-149 (2011).
6. Tabas, I. & Ron, D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. *Nat Cell Biol* **13**, 184-190 (2011).
7. Bettigole, S.E. *et al.* The transcription factor XBP1 is selectively required for eosinophil differentiation. *Nat Immunol* **16**, 829-837 (2015).
8. Chevet, E., Hetz, C. & Samali, A. Endoplasmic reticulum stress-activated cell reprogramming in oncogenesis. *Cancer Discov* **5**, 586-597 (2015).
9. Grootjans, J., Kaser, A., Kaufman, R.J. & Blumberg, R.S. The unfolded protein response in immunity and inflammation. *Nat Rev Immunol* **16**, 469-484 (2016).
10. Hetz, C., Chevet, E. & Harding, H.P. Targeting the unfolded protein response in disease. *Nat Rev Drug Discov* **12**, 703-719 (2013).
11. Lin, J.H., Walter, P. & Yen, T.S. Endoplasmic reticulum stress in disease pathogenesis. *Annu Rev Pathol* **3**, 399-425 (2008).

12. Chen, X. & Cubillos-Ruiz, J.R. Endoplasmic reticulum stress signals in the tumour and its microenvironment. *Nature Reviews Cancer* (2020).
13. Chen, X. *et al.* XBP1 promotes triple-negative breast cancer by controlling the HIF1alpha pathway. *Nature* **508**, 103-107 (2014).
14. Harnoss, J.M. *et al.* IRE1 α disruption in triple-negative breast cancer cooperates with anti-angiogenic therapy by reversing ER stress adaptation and remodeling the tumor microenvironment. *Cancer Res* (2020).
15. Harnoss, J.M. *et al.* Disruption of IRE1 α through its kinase domain attenuates multiple myeloma. *Proc Natl Acad Sci U S A* **116**, 16420-16429 (2019).
16. Urrea, H., Dufey, E., Avril, T., Chevet, E. & Hetz, C. Endoplasmic Reticulum Stress and the Hallmarks of Cancer. *Trends Cancer* **2**, 252-262 (2016).
17. Wang, M. & Kaufman, R.J. The impact of the endoplasmic reticulum protein-folding environment on cancer development. *Nat Rev Cancer* **14**, 581-597 (2014).
18. Cox, J.S., Shamu, C.E. & Walter, P. Transcriptional induction of genes encoding endoplasmic reticulum resident proteins requires a transmembrane protein kinase. *Cell* **73**, 1197-1206 (1993).
19. Lee, K.P. *et al.* Structure of the dual enzyme Ire1 reveals the basis for catalysis and regulation in nonconventional RNA splicing. *Cell* **132**, 89-100 (2008).
20. Gardner, B.M. & Walter, P. Unfolded proteins are Ire1-activating ligands that directly induce the unfolded protein response. *Science* **333**, 1891-1894 (2011).

21. Han, D. *et al.* IRE1alpha kinase activation modes control alternate endoribonuclease outputs to determine divergent cell fates. *Cell* **138**, 562-575 (2009).
22. Korennykh, A.V. *et al.* The unfolded protein response signals through high-order assembly of Ire1. *Nature* **457**, 687-693 (2009).
23. Shamu, C.E. & Walter, P. Oligomerization and phosphorylation of the Ire1p kinase during intracellular signaling from the endoplasmic reticulum to the nucleus. *EMBO J* **15**, 3028-3039 (1996).
24. Tirasophon, W., Welihinda, A.A. & Kaufman, R.J. A stress response pathway from the endoplasmic reticulum to the nucleus requires a novel bifunctional protein kinase/endoribonuclease (Ire1p) in mammalian cells. *Genes Dev* **12**, 1812-1824 (1998).
25. Hollien, J. *et al.* Regulated Ire1-dependent decay of messenger RNAs in mammalian cells. *J Cell Biol* **186**, 323-331 (2009).
26. Hollien, J. & Weissman, J.S. Decay of endoplasmic reticulum-localized mRNAs during the unfolded protein response. *Science* **313**, 104-107 (2006).
27. Maurel, M., Chevet, E., Tavernier, J. & Gerlo, S. Getting RIDD of RNA: IRE1 in cell fate regulation. *Trends Biochem Sci* **39**, 245-254 (2014).
28. Brodsky, J.L. Cleaning up: ER-associated degradation to the rescue. *Cell* **151**, 1163-1167 (2012).
29. Calton, M. *et al.* IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. *Nature* **415**, 92-96 (2002).

30. Shen, X. *et al.* Complementary signaling pathways regulate the unfolded protein response and are required for *C. elegans* development. *Cell* **107**, 893-903 (2001).
31. Yoshida, H., Matsui, T., Yamamoto, A., Okada, T. & Mori, K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. *Cell* **107**, 881-891 (2001).
32. Jurkin, J. *et al.* The mammalian tRNA ligase complex mediates splicing of XBP1 mRNA and controls antibody secretion in plasma cells. *EMBO J* **33**, 2922-2936 (2014).
33. Lu, Y., Liang, F.X. & Wang, X. A synthetic biology approach identifies the mammalian UPR RNA ligase RtcB. *Mol Cell* **55**, 758-770 (2014).
34. Peschek, J., Acosta-Alvear, D., Mendez, A.S. & Walter, P. A conformational RNA zipper promotes intron ejection during non-conventional XBP1 mRNA splicing. *EMBO Rep* **16**, 1688-1698 (2015).
35. Hooks, K.B. & Griffiths-Jones, S. Conserved RNA structures in the non-canonical Hac1/Xbp1 intron. *RNA Biol* **8**, 552-556 (2011).
36. Lhomond, S. *et al.* Dual IRE1 RNase functions dictate glioblastoma development. *EMBO Mol Med* **10** (2018).
37. Kimmig, P. *et al.* The unfolded protein response in fission yeast modulates stability of select mRNAs to maintain protein homeostasis. *Elife* **1**, e00048 (2012).

38. Coelho, D.S. *et al.* Xbp1-independent Ire1 signaling is required for photoreceptor differentiation and rhabdomere morphogenesis in *Drosophila*. *Cell Rep* **5**, 791-801 (2013).
39. Gaddam, D., Stevens, N. & Hollien, J. Comparison of mRNA localization and regulation during endoplasmic reticulum stress in *Drosophila* cells. *Mol Biol Cell* **24**, 14-20 (2013).
40. Hollien, J. Evolution of the unfolded protein response. *Biochim Biophys Acta* **1833**, 2458-2463 (2013).
41. Moore, K. & Hollien, J. Ire1-mediated decay in mammalian cells relies on mRNA sequence, structure, and translational status. *Mol Biol Cell* **26**, 2873-2884 (2015).
42. Moore, K.A., Plant, J.J., Gaddam, D., Craft, J. & Hollien, J. Regulation of sumo mRNA during endoplasmic reticulum stress. *PLoS One* **8**, e75723 (2013).
43. Oikawa, D., Tokuda, M., Hosoda, A. & Iwawaki, T. Identification of a consensus element recognized and cleaved by IRE1 alpha. *Nucleic Acids Res* **38**, 6265-6273 (2010).
44. So, J.S. *et al.* Silencing of lipid metabolism genes through IRE1alpha-mediated mRNA decay lowers plasma lipids in mice. *Cell Metab* **16**, 487-499 (2012).
45. Chang, T.K. *et al.* Coordination between Two Branches of the Unfolded Protein Response Determines Apoptotic Cell Fate. *Mol Cell* **71**, 629-636 e625 (2018).
46. Lam, M., Marsters, S.A., Ashkenazi, A. & Walter, P. Misfolded proteins bind and activate death receptor 5 to trigger apoptosis during unresolved endoplasmic reticulum stress. *Elife* **9** (2020).

47. Lu, M. *et al.* Opposing unfolded-protein-response signals converge on death receptor 5 to control apoptosis. *Science* **345**, 98-101 (2014).
48. Bae, D., Moore, K.A., Mella, J.M., Hayashi, S.Y. & Hollien, J. Degradation of Blos1 mRNA by IRE1 repositions lysosomes and protects cells from stress. *J Cell Biol* **218**, 1118-1127 (2019).
49. Dufey, E. *et al.* Genotoxic stress triggers the activation of IRE1alpha-dependent RNA decay to modulate the DNA damage response. *Nat Commun* **11**, 2401 (2020).
50. Tang, C.H. *et al.* Phosphorylation of IRE1 at S729 regulates RIDD in B cells and antibody production after immunization. *J Cell Biol* **217**, 1739-1755 (2018).
51. Guydosh, N.R., Kimmig, P., Walter, P. & Green, R. Regulated Ire1-dependent mRNA decay requires no-go mRNA degradation to maintain endoplasmic reticulum homeostasis in *S. pombe*. *Elife* **6** (2017).
52. Prischi, F., Nowak, P.R., Carrara, M. & Ali, M.M. Phosphoregulation of Ire1 RNase splicing activity. *Nat Commun* **5**, 3554 (2014).
53. Aragon, T. *et al.* Messenger RNA targeting to endoplasmic reticulum stress signalling sites. *Nature* **457**, 736-740 (2009).
54. Belyy, V., Tran, N.H. & Walter, P. Quantitative microscopy reveals dynamics and fate of clustered IRE1alpha. *Proc Natl Acad Sci U S A* **117**, 1533-1542 (2020).
55. Ghosh, R. *et al.* Allosteric inhibition of the IRE1alpha RNase preserves cell viability and function during endoplasmic reticulum stress. *Cell* **158**, 534-548 (2014).

56. Li, H., Korennykh, A.V., Behrman, S.L. & Walter, P. Mammalian endoplasmic reticulum stress sensor IRE1 signals by dynamic clustering. *Proc Natl Acad Sci U S A* **107**, 16113-16118 (2010).
57. Ricci, D. *et al.* Clustering of IRE1alpha depends on sensing ER stress but not on its RNase activity. *FASEB J* **33**, 9811-9827 (2019).
58. Lopes, R., Agami, R. & Korkmaz, G. GRO-seq, A Tool for Identification of Transcripts Regulating Gene Expression. *Methods Mol Biol* **1543**, 45-55 (2017).
59. Cross, B.C. *et al.* The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule. *Proc Natl Acad Sci U S A* **109**, E869-878 (2012).
60. Harrington, P.E. *et al.* Unfolded Protein Response in Cancer: IRE1alpha Inhibition by Selective Kinase Ligands Does Not Impair Tumor Cell Viability. *ACS Med Chem Lett* **6**, 68-72 (2015).
61. Joshi, A. *et al.* Molecular mechanisms of human IRE1 activation through dimerization and ligand binding. *Oncotarget* **6**, 13019-13035 (2015).
62. Tam, A.B., Koong, A.C. & Niwa, M. Ire1 has distinct catalytic mechanisms for XBP1/HAC1 splicing and RIDD. *Cell Rep* **9**, 850-858 (2014).
63. Ferri, E. *et al.* Activation of the IRE1 RNase through remodeling of the kinase front pocket by ATP-competitive ligands. *Nat Commun* **11**, 6387 (2020).
64. Korennykh, A.V. *et al.* Structural and functional basis for RNA cleavage by Ire1. *BMC Biol* **9**, 47 (2011).

65. Niwa, M., Sidrauski, C., Kaufman, R.J. & Walter, P. A role for presenilin-1 in nuclear accumulation of Ire1 fragments and induction of the mammalian unfolded protein response. *Cell* **99**, 691-702 (1999).
66. Shemorry, A. *et al.* Caspase-mediated cleavage of IRE1 controls apoptotic cell commitment during endoplasmic reticulum stress. *Elife* **8** (2019).
67. Zhang, Z. *et al.* TIPE1 induces apoptosis by negatively regulating Rac1 activation in hepatocellular carcinoma cells. *Oncogene* **34**, 2566-2574 (2015).
68. Sundaram, A., Plumb, R., Appathurai, S. & Mariappan, M. The Sec61 translocon limits IRE1alpha signaling during the unfolded protein response. *Elife* **6** (2017).
69. Peschek, J. & Walter, P. tRNA ligase structure reveals kinetic competition between non-conventional mRNA splicing and mRNA decay. *Elife* **8** (2019).
70. Wu, T.D. & Watanabe, C.K. GMAP: a genomic mapping and alignment program for mRNA and EST sequences. *Bioinformatics* **21**, 1859-1875 (2005).
71. Bendtsen, J.D., Nielsen, H., von Heijne, G. & Brunak, S. Improved prediction of signal peptides: SignalP 3.0. *J Mol Biol* **340**, 783-795 (2004).

a **Figure 1**

Figure S1

	Gene name	IRE1 dep. down-reg. (RNAseq)	Fold down-reg. over transcription (RNAseq/GROseq)	Signal sequence
1	AIM2	37%	1.67	None
2	ALDH1A3	37%	1.25	None
3	ATF5	35%	1.58	None
4	ATP9A	41%	1.44	None
5	B3GNT8	39%	1.89	Type I
6	BCAM	79%	1.71	Type I
7	BLOC1S1	30%	1.31	None
8	BMP4	49%	1.32	Type I
9	CALHM2	31%	1.33	None
10	CCDC69	33%	1.41	None
11	CD59	42%	1.65	Type I
12	CDKN1C	47%	1.65	Type I
13	CEP162	41%	1.93	None
14	CFAP45	32%	1.96	None
15	CHST4	45%	3.29	None
16	CTSO	45%	1.33	Type I
17	DGAT2	81%	4.07	Type II
18	DSEL	37%	1.30	Type I
19	ERCC6	30%	1.28	None
20	FAM117B	30%	1.43	None
21	FAM63A	53%	1.29	None
22	FILIP1L	50%	1.31	None
23	FITM2	31%	2.18	Type II
24	GATSL2	29%	1.51	None
25	GBA	41%	1.38	Type I
26	GJD3	32%	1.36	Type I
27	GPC1	33%	1.34	Type I
28	HAPLN3	40%	2.01	Type I
29	HIP1	40%	1.45	None
30	IL31RA	41%	1.27	Type I
31	KIAA1467	33%	1.58	None
32	LRRN4	32%	3.05	Type I
33	MAP3K5	31%	1.30	None
34	MAST4	35%	1.30	None
35	METTL7A	41%	2.15	None
36	MFAP2	37%	1.90	Type I
37	MILR1	42%	2.12	Type I
38	OAS2	41%	1.32	None
39	PIGQ	33%	1.38	None
40	PROS1	38%	4.38	Type I
41	RGS7	35%	1.39	None
42	RNF213	33%	1.41	None
43	SIX2	37%	1.60	None
44	SNN	32%	1.78	Type II
45	SRXN1	36%	1.24	None
46	SUOX	32%	1.32	None
47	TGOLN2	56%	2.43	Type I
48	TLR2	43%	1.68	Type I
49	TMEM19	37%	1.86	None
50	TNFAIP8L1	30%	4.04	None
51	TRIM16L	32%	1.51	None
52	TRIM62	30%	1.34	None
53	WT1	50%	1.49	None
54	ZFHX4	36%	1.27	None

Table S1

Molecular and cellular functions	p-value range	# genes
Cell death and survival	1.41e-02 – 6.16e-05	11
Cell signaling	1.18e-02 – 7.77e-05	4
Post-translational modification	8.91e-03 – 7.77e-05	6
Cell morphology	1.41e-02 - 2.44e-04	10
Cell cycle	1.41e-02 - 3.75e-04	8

Table S2

GO biological process	p-value	# genes
Response to endoplasmic reticulum stress (GO:0034976)	1.87E-31	46
Endoplasmic reticulum to Golgi vesicle-mediated transport (GO:0006888)	2.89E-26	37
IRE1-mediated unfolded protein response (GO:0036498)	6.73E-17	18
Cellular response to unfolded protein (GO:0034620)	3.78E-16	23
Protein N-linked glycosylation via asparagine (GO:0018279)	3.80E-15	14
ERAD pathway (GO:0036503)	8.90E-15	19
COPII-coated vesicle cargo loading (GO:0090110)	1.46E-12	10
Protein folding in endoplasmic reticulum (GO:0034975)	3.74E-06	5
Somatostatin signaling pathway (GO:0038170)	7.45E-06	4
SRP-dependent cotranslational protein targeting to membrane (GO:0006614)	7.50E-06	10
COPI coating of Golgi vesicle (GO:0048205)	1.23E-05	4
Protein K69-linked ufmylation (GO:1990592)	2.11E-04	3
Mannose trimming involved in glycoprotein ERAD pathway (GO:1904382)	2.11E-04	3

Table S3

Figure S2

Gene	Transcript	Pos	Structure	Loop	Stem	Energy	FL	FS	Type
Exact consensus sequence									
MAST4	XM.011543384.2	560	((((((((CUGCAG))))))))))	Exact	11	-11.60			
PROS1	NM.000313.4	2820	((((((((CUGCAGU))))))))	Exact	9	-9.40			
DGAT2	BC015234.1	260	((((((((CUGCAGU)))))).)))	Exact	9	-9.00			0P
BLOC1S1	NM.001487.2	360	((((((((CUGCAGU))))))))	Exact	6	-8.70			0P
RNF213	NM.001256071.3	9055	((((((((CUGCAG))))))))	Exact	8	-7.30			
ERCC6	NM.001346440.2	20483	((((((((CUGCAG).))))))))	Exact	8	-5.70			
SUOX	XM.017019907.2	5148	((((((((CUGCAGAC))))))))	Exact	6	-4.90			
HAPLN3	XR.931756.3	1184	((((((((CUGCAGGG)).))))))	Exact	8	-4.80			
ATF5	NM.012068.6	249	((((((((CUGCAGC)).))))))	Exact	6	-3.80			
IL31RA	NM.139017.7	5705	((((((((CUGCAGC))))))))	Exact	4	-3.20			
TGOLN2	NM.006464.3	390	(((((CUGCAGA))))))	Exact	4	-2.90			0P
GBA	NM.000157.4	612	(((((CUGCAGUU)).)))	Exact	4	-1.70			0P
CD59	NM.203331.2	78	(((((CUGCAGU))))))	Exact	4	-1.10			0P
MILR1	XM.024450707.1	1433	((((((((CUGCAGU))))))))	Exact	7	-0.70			
TRIM62	NM.018207.3	1082	(((((CUGCAGC))))))	Exact	4	-0.60			
CASTOR2	NM.001145064.3	7422	(((((CUGCAGAU))))))	Exact	4	-0.30			
LRRN4	NM.152611.5	2378	(((((CUGCAGC))))))	Exact	3	-0.10			
ZFHx4	NM.024721.5	4348	(((((CUGCAGCC))))))	Exact	3	0.10			
FAM234B	NM.020853.2	1361	(((((CUGCAGAU)).))))	Exact	5	1.10			
PIGQ	NM.004204.3	972	(((((CUGCAG)).)))	Exact	5	2.60			0P
CEP162	XM.017010483.2	605	((((((((CUGCAGG).))))))))	Exact	7	3.70			
BMP4	NM.130850.3	186	(((((CUGCAG))))))	Exact	5	3.90			0P
Variant consensus sequence									
WT1	BC032861.2	120	((((((((CaGCAGG)))))).)))	Var2	9	-9.70			0P
FITM2	NM.001080472.4	327	((((((((CUGCgGC))))))))	Var5	8	-7.70			
TMEM19	NM.018279.4	1581	(((((CUGCuGC))))))	Var5	7	-5.30			
TRIM16L	NM.001037330.3	967	((((((((CaGCAGU)))))).)))	Var2	8	-5.20			
GPC1	NM.002081.3	1200	(((((CgGCAGC))))))	Var2	7	-2.70			
B3GNT8	NM.198540.2	1417	(((((CUGCgGC))))))	Var5	4	-2.00			
MAP3K5	NM.005923.4	2467	(((((CaGCAGA).))))	Var2	6	-1.70			
DSEL	NM.032160.3	4897	(((((CaGCAGA).))))	Var2	7	0.00			
Non-canonical stem-loop									
ATP9A	NM.006045.3	621	(((((CUGCgG))))).))	Var5	7	-5.60	×		
BCAM	NM.005581.3	293	(((((CcGCAGU))))))	Var2	4	-4.40		×	3P
CALHM2	NM.015916.5	1824	(((((CaGCAG))))))	Var2	3	0.50	×	×	
CCDC69	NM.015621.2	786	(((((CaGCAG))))))	Var2	3	-0.10	×	×	3P
CDKN1C	NM.000076.2	1340	(((((CcGCAGAG))))))	Var2	4	-3.20	×	×	
CTSO	NM.001334.3	308	(((((CaGCAGA))))))	Var2	4	0.70		×	
FAM117B	NM.173511.4	448	(((((CcGCAGGC))))))	Var2	3	-2.30	×	×	
FILIP1L	NM.001387850.1	5557	(((((CaGCAGU))))))	Var2	4	-2.70		×	
HIP1	NM.005338.7	296	(((((CUGCuGGA))))).)))	Var5	7	-6.20	×		
MFAP2	NM.002403.3	290	(((((CUGCcG).))))	Var5	5	0.00	×		3P
RGS7	XM.017002011.2	1695	(((((CUGCcGG))))))	Var5	3	2.80		×	
SIX2	NM.016932.4	720	(((((CUGCcGU))))))	Var5	3	-1.10		×	3P
SNN	NM.003498.5	108	(((((CUGCgGCU).))))	Var5	6	-3.50	×		3P
SRXN1	NM.080725.3	174	(((((CUGCcGUC).))))))	Var5	8	-6.70	×		
TNFAIP8L1	NM.152362.1	219	(((((CUGCuGCG))))))	Var5	3	3.60	×	×	3P
Consensus sequence plus stem-loop not found									
AIM2	NA								3P
ALDH1A3	NA								
CFAP45	NA								3P
CHST4	NA								
GJD3	NA								
METTL7A	NA								
MINDY1	NA								
OAS2	NA								3P
TLR2	NA								

Table S4

Figure 3

Figure S3

Figure 4

Figure S4

Figure 5

Figure S5